Overview

Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if bortezomib (Velcade) is effective in the treatment of refractory cGVHD.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor Research Institute
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
Bortezomib